Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
Jada Lewis,*Dennis W. Dickson,*Wen-Lang Lin,Louise Chisholm,Anthony Corral,Graham Jones,Shu-Hui Yen,Naruhiko Sahara,Lisa Skipper,Debra Yager,Chris Eckman,John Hardy,Mike Hutton,Eileen McGowan
JNPL3 transgenic mice expressing a mutant tau protein,
which develop neurofibrillary tangles and progressive motor
disturbance,were crossed with Tg2576 transgenic mice expressing mutant
-amyloidprecursor protein (APP), thus modulating the APP-A
(-amyloidpeptide) environment. The resulting double mutant
(tau/APP) progenyand the Tg2576 parental strain developed A
deposits at the sameage; however, relative to JNPL3 mice, the double
mutants exhibitedneurofibrillary tangle pathology that was
substantially enhancedin the limbic system and olfactory cortex. These
results indicatethat either APP or A influences the formation of
neurofibrillarytangles. The interaction between A and tau
pathologies in thesemice supports the hypothesis that a similar
interaction occursin Alzheimer's disease.
Birdsall Building, Mayo Clinic Jacksonville, 4500 San Pablo Road,
Jacksonville, FL 32224, USA.
*
These authors contributed equally to this report.
To whom correspondence should be addressed. E-mail:
hutton.michael{at}mayo.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
Virginia M.-Y. Lee (24 August 2001) Science293 (5534), 1446.
[DOI: 10.1126/science.1064684] |Summary »|Full Text »|PDF »
REPORTS
J. Götz, F. Chen, J. van Dorpe, and R. M. Nitsch (24 August 2001) Science293 (5534), 1491.
[DOI: 10.1126/science.1062097] |Abstract »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Epilepsy and Cognitive Impairments in Alzheimer Disease.
Relevance of Transgenic Mouse Models to Human Alzheimer Disease.
D. A. Morrissette, A. Parachikova, K. N. Green, and F. M. LaFerla (2009)
J. Biol. Chem.
284, 6033-6037
|Abstract »|Full Text »|PDF »
Increasing Cu bioavailability inhibits A{beta} oligomers and tau phosphorylation.
P. J. Crouch, L. W. Hung, P. A. Adlard, M. Cortes, V. Lal, G. Filiz, K. A. Perez, M. Nurjono, A. Caragounis, T. Du, et al. (2009)
PNAS
106, 381-386
|Abstract »|Full Text »|PDF »
Blocking A{beta}42 Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between A{beta} and Tau Pathology.
S. Oddo, A. Caccamo, B. Tseng, D. Cheng, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla (2008)
J. Neurosci.
28, 12163-12175
|Abstract »|Full Text »|PDF »
Dementia of the Alzheimer Type.
J. J. Jalbert, L. A. Daiello, and K. L. Lapane (2008)
Epidemiol. Rev.
30, 15-34
|Abstract »|Full Text »|PDF »
Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome.
J. Shi, T. Zhang, C. Zhou, M. O. Chohan, X. Gu, J. Wegiel, J. Zhou, Y.-W. Hwang, K. Iqbal, I. Grundke-Iqbal, et al. (2008)
J. Biol. Chem.
283, 28660-28669
|Abstract »|Full Text »|PDF »
Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice.
J. A. Rodriguez-Navarro, A. Gomez, I. Rodal, J. Perucho, A. Martinez, V. Furio, I. Ampuero, M. J. Casarejos, R. M. Solano, J. G. de Yebenes, et al. (2008)
Hum. Mol. Genet.
17, 3128-3143
|Abstract »|Full Text »|PDF »
Amyloid Plaque and Neurofibrillary Tangle Pathology in a Regulatable Mouse Model of Alzheimer's Disease.
J. B. Paulson, M. Ramsden, C. Forster, M. A. Sherman, E. McGowan, and K. H. Ashe (2008)
Am. J. Pathol.
173, 762-772
|Abstract »|Full Text »|PDF »
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.
J. S. K. Kauwe, C. Cruchaga, K. Mayo, C. Fenoglio, S. Bertelsen, P. Nowotny, D. Galimberti, E. Scarpini, J. C. Morris, A. M. Fagan, et al. (2008)
PNAS
105, 8050-8054
|Abstract »|Full Text »|PDF »
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity.
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al. (2008)
Brain
131, 651-664
|Abstract »|Full Text »|PDF »
Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2.
D. M. Wilcock, M. R. Lewis, W. E. Van Nostrand, J. Davis, M. L. Previti, N. Gharkholonarehe, M. P. Vitek, and C. A. Colton (2008)
J. Neurosci.
28, 1537-1545
|Abstract »|Full Text »|PDF »
The Potential for -Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy.
M.-M. Mocanu, A. Nissen, K. Eckermann, I. Khlistunova, J. Biernat, D. Drexler, O. Petrova, K. Schonig, H. Bujard, E. Mandelkow, et al. (2008)
J. Neurosci.
28, 737-748
|Abstract »|Full Text »|PDF »
Induction of Tau Pathology by Intracerebral Infusion of Amyloid- -Containing Brain Extract and by Amyloid- Deposition in APP x Tau Transgenic Mice.
T. Bolmont, F. Clavaguera, M. Meyer-Luehmann, M. C. Herzig, R. Radde, M. Staufenbiel, J. Lewis, M. Hutton, M. Tolnay, and M. Jucker (2007)
Am. J. Pathol.
171, 2012-2020
|Abstract »|Full Text »|PDF »
Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements.
A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson (2007)
J. Neurosci.
27, 9115-9129
|Abstract »|Full Text »|PDF »
Actin-binding Proteins Coronin-1a and IBA-1 Are Effective Microglial Markers for Immunohistochemistry.
Z. Ahmed, G. Shaw, V. P. Sharma, C. Yang, E. McGowan, and D. W. Dickson (2007)
J. Histochem. Cytochem.
55, 687-700
|Abstract »|Full Text »|PDF »
Reducing Endogenous Tau Ameliorates Amyloid {beta}-Induced Deficits in an Alzheimer's Disease Mouse Model.
E. D. Roberson, K. Scearce-Levie, J. J. Palop, F. Yan, I. H. Cheng, T. Wu, H. Gerstein, G.-Q. Yu, and L. Mucke (2007)
Science
316, 750-754
|Abstract »|Full Text »|PDF »
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy.
Z. Berger, H. Roder, A. Hanna, A. Carlson, V. Rangachari, M. Yue, Z. Wszolek, K. Ashe, J. Knight, D. Dickson, et al. (2007)
J. Neurosci.
27, 3650-3662
|Abstract »|Full Text »|PDF »
The Genetics of Alzheimer's Disease.
C. K. Chai (2007)
American Journal of Alzheimer's Disease and Other Dementias
22, 37-41
|Abstract »|PDF »
Activation of PAR-1 Kinase and Stimulation of Tau Phosphorylation by Diverse Signals Require the Tumor Suppressor Protein LKB1.
Selective vulnerability of different types of commissural neurons for amyloid {beta}-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology.
E. Capetillo-Zarate, M. Staufenbiel, D. Abramowski, C. Haass, A. Escher, C. Stadelmann, H. Yamaguchi, O. D. Wiestler, and D. R. Thal (2006)
Brain
129, 2992-3005
|Abstract »|Full Text »|PDF »
p25/Cyclin-Dependent Kinase 5 Induces Production and Intraneuronal Accumulation of Amyloid beta In Vivo.
J. C. Cruz, D. Kim, L. Y. Moy, M. M. Dobbin, X. Sun, R. T. Bronson, and L.-H. Tsai (2006)
J. Neurosci.
26, 10536-10541
|Abstract »|Full Text »|PDF »
Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation.
H. Oakley, S. L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Guillozet-Bongaarts, M. Ohno, J. Disterhoft, L. Van Eldik, et al. (2006)
J. Neurosci.
26, 10129-10140
|Abstract »|Full Text »|PDF »
Cortical Neuronal and Glial Pathology in TgTauP301L Transgenic Mice: Neuronal Degeneration, Memory Disturbance, and Phenotypic Variation.
T. Murakami, E. Paitel, T. Kawarabayashi, M. Ikeda, M. A. Chishti, C. Janus, E. Matsubara, A. Sasaki, T. Kawarai, A. L. Phinney, et al. (2006)
Am. J. Pathol.
169, 1365-1375
|Abstract »|Full Text »|PDF »
NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.
C. A. Colton, M. P. Vitek, D. A. Wink, Q. Xu, V. Cantillana, M. L. Previti, W. E. Van Nostrand, J. B. Weinberg, and H. Dawson (2006)
PNAS
103, 12867-12872
|Abstract »|Full Text »|PDF »
Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits.
K. Schindowski, A. Bretteville, K. Leroy, S. Begard, J.-P. Brion, M. Hamdane, and L. Buee (2006)
Am. J. Pathol.
169, 599-616
|Abstract »|Full Text »|PDF »
Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices..
N. Shahani, S. Subramaniam, T. Wolf, C. Tackenberg, and R. Brandt (2006)
J. Neurosci.
26, 6103-6114
|Abstract »|Full Text »|PDF »
Effects of secreted oligomers of amyloid {beta}-protein on hippocampal synaptic plasticity: a potent role for trimers.
M. Townsend, G. M. Shankar, T. Mehta, D. M. Walsh, and D. J. Selkoe (2006)
J. Physiol.
572, 477-492
|Abstract »|Full Text »|PDF »
Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether?.
M. P. Murphy and T. E. Golde (2006)
Neurology
66, S65-S68
|Full Text »|PDF »
Temporal Profile of Amyloid-beta (Abeta) Oligomerization in an in Vivo Model of Alzheimer Disease: A LINK BETWEEN Abeta AND TAU PATHOLOGY.
S. Oddo, A. Caccamo, L. Tran, M. P. Lambert, C. G. Glabe, W. L. Klein, and F. M. LaFerla (2006)
J. Biol. Chem.
281, 1599-1604
|Abstract »|Full Text »|PDF »
Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy: AGGREGATION IS TOXIC TO CELLS BUT CAN BE REVERSED BY INHIBITOR DRUGS.
I. Khlistunova, J. Biernat, Y. Wang, M. Pickhardt, M. von Bergen, Z. Gazova, E. Mandelkow, and E.-M. Mandelkow (2006)
J. Biol. Chem.
281, 1205-1214
|Abstract »|Full Text »|PDF »
Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases.
A. E. Lovett-Racke, P. D. Cravens, A. R. Gocke, M. K. Racke, and O. Stuve (2005)
Arch Neurol
62, 1810-1813
|Full Text »|PDF »
Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L).
M. Ramsden, L. Kotilinek, C. Forster, J. Paulson, E. McGowan, K. SantaCruz, A. Guimaraes, M. Yue, J. Lewis, G. Carlson, et al. (2005)
J. Neurosci.
25, 10637-10647
|Abstract »|Full Text »|PDF »
Translational Research on the Way to Effective Therapy for Alzheimer Disease.
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease.
A.J. Myers, M. Kaleem, L. Marlowe, A.M. Pittman, A.J. Lees, H.C. Fung, J. Duckworth, D. Leung, A. Gibson, C.M. Morris, et al. (2005)
Hum. Mol. Genet.
14, 2399-2404
|Abstract »|Full Text »|PDF »
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function.
K. SantaCruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes, M. DeTure, M. Ramsden, E. McGowan, et al. (2005)
Science
309, 476-481
|Abstract »|Full Text »|PDF »
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
W. Noble, E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, K. Gaynor, L. Wang, J. LaFrancois, B. Feinstein, et al. (2005)
PNAS
102, 6990-6995
|Abstract »|Full Text »|PDF »
Sleep-wake states ub transgenic mouse models overexpressing the human {beta}-amyloid precursor protein.
S. Huitron-Resendiz, M. Sanchez-Alavez, and J. R. Criado (2005)
American Journal of Alzheimer's Disease and Other Dementias
20, 87-90
|Abstract »|PDF »
Independent accumulations of tau and amyloid {beta}-protein in the human entorhinal cortex.
T. Katsuno, M. Morishima-Kawashima, Y. Saito, H. Yamanouchi, S. Ishiura, S. Murayama, and Y. Ihara (2005)
Neurology
64, 687-692
|Abstract »|Full Text »|PDF »
Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice.
D. Terwel, R. Lasrado, J. Snauwaert, E. Vandeweert, C. Van Haesendonck, P. Borghgraef, and F. Van Leuven (2005)
J. Biol. Chem.
280, 3963-3973
|Abstract »|Full Text »|PDF »
Mouse Models of Human Neurodegenerative Disorders: Requirements for Medication Development.
F. E. Bloom, J. F. Reilly, J. M. Redwine, C.-C. Wu, W. G. Young, and J. H. Morrison (2005)
Arch Neurol
62, 185-187
|Abstract »|Full Text »|PDF »
Defining Molecular Targets to Prevent Alzheimer Disease.
{beta}-Amyloid-Induced Neurodegeneration and Protection by Structurally Diverse Microtubule-Stabilizing Agents.
M. L. Michaelis, S. Ansar, Y. Chen, E. R. Reiff, K. I. Seyb, R. H. Himes, K. L. Audus, and G. I. Georg (2005)
J. Pharmacol. Exp. Ther.
312, 659-668
|Abstract »|Full Text »|PDF »
Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice.
M. Ikeda, M. Shoji, T. Kawarai, T. Kawarabayashi, E. Matsubara, T. Murakami, A. Sasaki, Y. Tomidokoro, Y. Ikarashi, H. Kuribara, et al. (2005)
Am. J. Pathol.
166, 521-531
|Abstract »|Full Text »|PDF »
Evaluation of the safety and immunogenicity of synthetic A{beta}42 (AN1792) in patients with AD.
A. J. Bayer, R. Bullock, R. W. Jones, D. Wilkinson, K. R. Paterson, L. Jenkins, S. B. Millais, and S. Donoghue (2005)
Neurology
64, 94-101
|Abstract »|Full Text »|PDF »
Increased tau Phosphorylation on Mitogen-Activated Protein Kinase Consensus Sites and Cognitive Decline in Transgenic Models for Alzheimer's Disease and FTDP-17: Evidence for Distinct Molecular Processes Underlying tau Abnormalities.
S. L. Lambourne, L. A. Sellers, T. G. Bush, S. K. Choudhury, P. C. Emson, Y.-H. Suh, and L. S. Wilkinson (2005)
Mol. Cell. Biol.
25, 278-293
|Abstract »|Full Text »|PDF »
Calcium Dyshomeostasis in {beta}-Amyloid and Tau-bearing Skeletal Myotubes.
R. A. Christensen, A. Shtifman, P. D. Allen, J. R. Lopez, and H. W. Querfurth (2004)
J. Biol. Chem.
279, 53524-53532
|Abstract »|Full Text »|PDF »
Neutralization of Transthyretin Reverses the Neuroprotective Effects of Secreted Amyloid Precursor Protein (APP) in APPSw Mice Resulting in Tau Phosphorylation and Loss of Hippocampal Neurons: Support for the Amyloid Hypothesis.
T. D. Stein, N. J. Anders, C. DeCarli, S. L. Chan, M. P. Mattson, and J. A. Johnson (2004)
J. Neurosci.
24, 7707-7717
|Abstract »|Full Text »|PDF »
The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor.
R. C. von Rotz, B. M. Kohli, J. Bosset, M. Meier, T. Suzuki, R. M. Nitsch, and U. Konietzko (2004)
J. Cell Sci.
117, 4435-4448
|Abstract »|Full Text »|PDF »
Down-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro: A POTENTIAL ROLE IN ALZHEIMER'S DISEASE.
C.-I Sze, M. Su, S. Pugazhenthi, P. Jambal, L.-J. Hsu, J. Heath, L. Schultz, and N.-S. Chang (2004)
J. Biol. Chem.
279, 30498-30506
|Abstract »|Full Text »|PDF »
Role for glyoxalase I in Alzheimer's disease.
F. Chen, M. A. Wollmer, F. Hoerndli, G. Munch, B. Kuhla, E. I. Rogaev, M. Tsolaki, A. Papassotiropoulos, and J. Gotz (2004)
PNAS
101, 7687-7692
|Abstract »|Full Text »|PDF »
D. J. Selkoe (2004)
Ann Intern Med
140, 627-638
|Full Text »|PDF »
Dimeric Amyloid {beta} Protein Rapidly Accumulates in Lipid Rafts followed by Apolipoprotein E and Phosphorylated Tau Accumulation in the Tg2576 Mouse Model of Alzheimer's Disease.
T. Kawarabayashi, M. Shoji, L. H. Younkin, L. Wen-Lang, D. W. Dickson, T. Murakami, E. Matsubara, K. Abe, K. H. Ashe, and S. G. Younkin (2004)
J. Neurosci.
24, 3801-3809
|Abstract »|Full Text »|PDF »
Neurofibrillary Tangles Mediate the Association of Amyloid Load With Clinical Alzheimer Disease and Level of Cognitive Function.
D. A. Bennett, J. A. Schneider, R. S. Wilson, J. L. Bienias, and S. E. Arnold (2004)
Arch Neurol
61, 378-384
|Abstract »|Full Text »|PDF »
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles.
V. M. Miller, C. M. Gouvion, B. L. Davidson, and H. L. Paulson (2004)
Nucleic Acids Res.
32, 661-668
|Abstract »|Full Text »|PDF »
Increased hippocampal neurogenesis in Alzheimer's disease.
K. Jin, A. L. Peel, X. O. Mao, L. Xie, B. A. Cottrell, D. C. Henshall, and D. A. Greenberg (2004)
PNAS
101, 343-347
|Abstract »|Full Text »|PDF »
{beta}-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture.
A. Ferrari, F. Hoerndli, T. Baechi, R. M. Nitsch, and J. Gotz (2003)
J. Biol. Chem.
278, 40162-40168
|Abstract »|Full Text »|PDF »
PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation.
J. G. Richards, G. A. Higgins, A.-M. Ouagazzal, L. Ozmen, J. N. C. Kew, B. Bohrmann, P. Malherbe, M. Brockhaus, H. Loetscher, C. Czech, et al. (2003)
J. Neurosci.
23, 8989-9003
|Abstract »|Full Text »|PDF »
Co-Localization of Glycogen Synthase Kinase-3 with Neurofibrillary Tangles and Granulovacuolar Degeneration in Transgenic Mice.
T. Ishizawa, N. Sahara, K. Ishiguro, J. Kersh, E. McGowan, J. Lewis, M. Hutton, D. W. Dickson, and S.-H. Yen (2003)
Am. J. Pathol.
163, 1057-1067
|Abstract »|Full Text »|PDF »
{alpha}7 Nicotinic Acetylcholine Receptors Mediate {beta}-Amyloid Peptide-induced Tau Protein Phosphorylation.
H.-Y. Wang, W. Li, N. J. Benedetti, and D. H. S. Lee (2003)
J. Biol. Chem.
278, 31547-31553
|Abstract »|Full Text »|PDF »
Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease.
T. C. Gamblin, F. Chen, A. Zambrano, A. Abraha, S. Lagalwar, A. L. Guillozet, M. Lu, Y. Fu, F. Garcia-Sierra, N. LaPointe, et al. (2003)
PNAS
100, 10032-10037
|Abstract »|Full Text »|PDF »
Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer's Disease.
W.-L. An, R. F. Cowburn, L. Li, H. Braak, I. Alafuzoff, K. Iqbal, I.-G. Iqbal, B. Winblad, and J.-J. Pei (2003)
Am. J. Pathol.
163, 591-607
|Abstract »|Full Text »|PDF »
Identification of a Mutant Amyloid Peptide That Predominantly Forms Neurotoxic Protofibrillar Aggregates.
I. Qahwash, K. L. Weiland, Y. Lu, R. W. Sarver, R. F. Kletzien, and R. Yan (2003)
J. Biol. Chem.
278, 23187-23195
|Abstract »|Full Text »|PDF »
Amyloid, Presenilins, and Alzheimer's Disease.
G. V. Gassen and W. Annaert (2003)
Neuroscientist
9, 117-126
|Abstract »|PDF »
Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New.
Genetic Modulation of Tau Phosphorylation in the Mouse.
J. Brich, F.-S. Shie, B. W. Howell, R. Li, K. Tus, E. K. Wakeland, L.-W. Jin, M. Mumby, G. Churchill, J. Herz, et al. (2003)
J. Neurosci.
23, 187-192
|Abstract »|Full Text »|PDF »
Increased Brain {beta}-Amyloid Load, Phosphorylated Tau, and Risk of Alzheimer Disease Associated With an Intronic CYP46 Polymorphism.
A. Papassotiropoulos, J. R. Streffer, M. Tsolaki, S. Schmid, D. Thal, F. Nicosia, V. Iakovidou, A. Maddalena, D. Lutjohann, E. Ghebremedhin, et al. (2003)
Arch Neurol
60, 29-35
|Abstract »|Full Text »|PDF »
Tau-Mediated Cytotoxicity in a Pseudohyperphosphorylation Model of Alzheimer's Disease.
Intraneuronal Alzheimer A{beta}42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology.
R. H. Takahashi, T. A. Milner, F. Li, E. E. Nam, M. A. Edgar, H. Yamaguchi, M. F. Beal, H. Xu, P. Greengard, and G. K. Gouras (2002)
Am. J. Pathol.
161, 1869-1879
|Abstract »|Full Text »|PDF »
Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.
B. Urbanc, L. Cruz, R. Le, J. Sanders, K. H. Ashe, K. Duff, H. E. Stanley, M. C. Irizarry, and B. T. Hyman (2002)
PNAS
99, 13990-13995
|Abstract »|Full Text »|PDF »
Passive Immunization against beta -Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer's Disease-causing Mutation.
M. H. Mohajeri, K. Saini, J. G. Schultz, M. A. Wollmer, C. Hock, and R. M. Nitsch (2002)
J. Biol. Chem.
277, 33012-33017
|Abstract »|Full Text »|PDF »
Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease.
A. Delacourte, N. Sergeant, D. Champain, A. Wattez, C.-A. Maurage, F. Lebert, F. Pasquier, and J.-P. David (2002)
Neurology
59, 398-407
|Abstract »|Full Text »|PDF »
Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.
K. Stamer, R. Vogel, E. Thies, E. Mandelkow, and E.-M. Mandelkow (2002)
J. Cell Biol.
156, 1051-1063
|Abstract »|Full Text »|PDF »
The JNK/c-Jun cascade and Alzheimer's disease.
H. Okazawa and S. Estus (2002)
American Journal of Alzheimer's Disease and Other Dementias
17, 79-88
|Abstract »|PDF »
Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease : Key to Elucidating Neurodegenerative Pathways and Identifying New Targets for Drug Discovery.
J. Q. Trojanowski (2002)
Am. J. Pathol.
160, 409-411
|Full Text »|PDF »
Stable {beta}-Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice.
J.-T. Gau, M. L. Steinhilb, T.-C. Kao, C. J. D'Amato, J. R. Gaut, K. A. Frey, and R. S. Turner (2002)
Am. J. Pathol.
160, 731-738
|Abstract »|Full Text »|PDF »
Plaques Associated with Tangles in Mouse Models of AD.
(2002)
Journal Watch Neurology
2002, 1
|Full Text »
Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease.
(2001)
Journal Watch Psychiatry
2001, 5
|Full Text »
beta -Amyloid peptides enhance alpha -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
E. Masliah, E. Rockenstein, I. Veinbergs, Y. Sagara, M. Mallory, M. Hashimoto, and L. Mucke (2001)
PNAS
|Abstract »|Full Text »|PDF »
Tau and Amyloid-{beta} Peptide: Linking the Molecular Markers of Alzheimer's Disease.
(2001)
Journal Watch (General)
2001, 8
|Full Text »
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Abeta 42 Fibrils.
J. Gotz, F. Chen, J. van Dorpe, and R. M. Nitsch (2001)
Science
293, 1491-1495
|Abstract »|Full Text »|PDF »
beta -Amyloid peptides enhance alpha -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
E. Masliah, E. Rockenstein, I. Veinbergs, Y. Sagara, M. Mallory, M. Hashimoto, and L. Mucke (2001)
PNAS
98, 12245-12250
|Abstract »|Full Text »|PDF »
-amyloid precursor protein (APP), thus modulating the APP-A
